Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Request for Inspection Under the Inspection by Accredited Persons Program, 50976-50977 [E8-20113]
Download as PDF
50976
Federal Register / Vol. 73, No. 169 / Friday, August 29, 2008 / Notices
plans to release a second version of the
formats in six to nine months, or
perhaps sooner, depending on the
nature of initial feedback. Once the
formats are stabilized, AHRQ plans to
release new versions annually. The
Agency will follow the same process for
formats developed for other settings.
AHRQ realizes that using Version 0.1
Beta paper forms is not the optimal way
to collect patient safety data. Over time,
computer software (developed in the
private sector) will make use of the
formats much more efficient. However,
because the Agency plans an early
second release of the Common Formats,
it cautions software developers to
understand that the first release of the
formats will likely be substantially
enhanced.
More information on the feedback
process can be obtained through
AHRQ’s PSO Web site: https://
www.pso.ahrq.gov/.
Dated: August 21, 2008.
Carolyn M. Clancy,
Director.
[FR Doc. E8–19910 Filed 8–28–08; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS-R–65]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services.
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Centers for Medicare & Medicaid
Services (CMS) is publishing the
following summary of proposed
collections for public comment.
Interested persons are invited to send
comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
mstockstill on PROD1PC66 with NOTICES
AGENCY:
VerDate Aug<31>2005
17:32 Aug 28, 2008
Jkt 214001
1. Type of Information Collection
Request: Extension of a currently
approved collection; Title of
Information Collection: Information
Collection Requirements in Final Peer
Review Organizations Sanction
Regulations—42 CFR 1004.4, 1004.50,
1004.60, and 1004.70; Use: The Peer
Review Improvement Act of 1982
amended Title XI of the Social Security
Act (the Act), creating the Utilization
and Quality Control Peer Review
Organization Program. Section 1156 of
the Act imposes obligations on health
care practitioners and others who
furnish or order services or items under
Medicare. This section also provides for
sanction actions, if the Secretary
determines that the obligations as stated
by this section are not met. Quality
Improvement Organizations (QIOs) are
responsible for identifying violations.
QIOs may allow practitioners or other
entities, opportunities to submit
relevant information before determining
that a violation has occurred. The
information collection requirements
contained in this information collection
request are used by the QIOs to collect
the information necessary to make their
decision. Form Number: CMS–R–65
(OMB# 0938–0444); Frequency:
Reporting—On occasion; Affected
Public: Business or other for-profit and
not-for-profit institutions; Number of
Respondents: 53; Total Annual
Responses: 53; Total Annual Hours:
14,310.
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, access CMS’ Web site
at https://www.cms.hhs.gov/
PaperworkReductionActof1995, or
e-mail your request, including your
address, phone number, OMB number,
and CMS document identifier, to
Paperwork@cms.hhs.gov, or call the
Reports Clearance Office on (410) 786–
1326.
In commenting on the proposed
information collections please reference
the document identifier or OMB control
number. To be assured consideration,
comments and recommendations must
be submitted in one of the following
ways by October 28, 2008:
1. Electronically. You may submit
your comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) accepting comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Attention: Document Identifier/OMB
Control Number ____, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
Dated: August 22, 2008.
Michelle Shortt,
Director, Regulations Development Group,
Office of Strategic Operations and Regulatory
Affairs.
[FR Doc. E8–19975 Filed 8–28–08; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0313]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Request for
Inspection Under the Inspection by
Accredited Persons Program
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
Fax written comments on the
collection of information by September
29, 2008.
DATES:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–0569. Also
include the FDA docket number found
in brackets in the heading of this
document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3793.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\29AUN1.SGM
29AUN1
Federal Register / Vol. 73, No. 169 / Friday, August 29, 2008 / Notices
Requests for Inspection Under the
Inspection by Accredited Persons
Program--21 U.S.C. 374(g) (OMB
Control Number 0910–0569)—Extension
Section 201 of the Medical Device
User Fee and Modernization Act of
2002, (Public Law 107–250), amended
section 704 of the Federal Food, Drug,
and Cosmetic Act by adding subsection
(g) (21 U.S.C. 374 (g)). This amendment
authorized FDA to establish a voluntary
third party inspection program
applicable to manufacturers of class II or
class III medical devices who meet
certain eligibility criteria. On September
15, 2005, FDA issued a guidance
entitled, ‘‘Requests for Inspection by an
Accredited Person Under the Inspection
by Accredited Persons Program
Authorized by Section 201 of the
Medical Device User Fee and
Modernization Act 2002,’’ https://
www.fda.gov/cdrh/comp/guidance/
1532.html. This guidance describes the
eligibility criteria and the process for
establishments to follow when
requesting FDA’s approval to have an
accredited person (AP), conduct a
quality system regulation inspection of
their establishment under the new
inspection by the Accredited Persons
Program (AP program), instead of FDA.
The AP program applies to
manufacturers who currently market
their medical devices in the United
States and who also market or plan to
market their devices in foreign
countries. Such manufacturers may
need current inspections of their
establishments to operate in global
commerce.
In order to meet the eligibility criteria
for requesting FDA approval to have an
AP conduct a quality system regulations
inspection of their establishment
instead of FDA, applicants must submit
a request with certain information. The
following information must be
submitted which shows that the
applicant:
(1) ‘‘Manufactures, prepares,
propagates, compounds, or processes’’
class II or class III medical devices,
(2) Markets at least one of the devices
in the United States,
(3) Markets or intends to market at
least one of the devices in one or more
50977
foreign countries when one or both of
the following two conditions are met:
(a) One of the foreign countries
certifies, accredits, or otherwise
recognizes the selected AP applicant as
a person authorized to conduct
inspections of device establishments, or
(b) A statement that the law of a
country where the applicant markets or
intends to market the device recognizes
an inspection conducted by the FDA or
an AP.
(4) Provided the most recent
inspection performed by FDA, or by an
AP under the AP program and
inspection was classified by FDA as
either ‘‘No Action Indicated’’ or
‘‘Voluntary Action Indicated, ‘‘and,
(5) Provided notice advising FDA of
their intent to use an AP, and
identifying the AP applicant selected.
In the Federal Register of June 3, 2008
(73 FR 31692), FDA published a 60-day
notice requesting public comment on
the information collection provisions.
No comments were received.
FDA estimates the burden for this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 U.S.C. Section
374(g)
1 There
Annual Frequency per
Response
No. of Respondents
100
1
Hours per
Response
100
Total Hours
15
1,500
are no capital costs or operating and maintenance costs associated with this collection of information.
There are approximately 8,000 foreign
and 10,000 domestic manufacturers of
medical devices. Approximately 5,000
of these firms only manufacture class I
devices and are, therefore, not eligible
for the AP program. In addition, 40
percent of the domestic firms do not
export devices and therefore are not
eligible to participate in the AP
program. Further, 10 to 15 percent of the
firms are not eligible due to the results
of their previous inspection. FDA
estimates there are 4,000 domestic
manufacturers and 4,000 foreign
manufacturers that are eligible for
inclusion under the AP program. Based
on communications with industry, FDA
estimates that on an annual basis
approximately 100 of these
manufacturers may submit a request to
use an AP in any given year.
mstockstill on PROD1PC66 with NOTICES
Total Annual
Responses
Dated: August 25, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–20113 Filed 8–28–08; 8:45 am]
17:32 Aug 28, 2008
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Emphasis Panel; Category A and B
Pathogens.
Date: September 18, 2008.
Time: 12 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817,
(Telephone Conference Call).
Contact Person: Lucy A. Ward, DVM, PhD,
Scientific Review Officer, Scientific Review
Program, Division of Extramual Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892, 301–594–
6635, lward@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 21, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–19916 Filed 8–28–08; 8:45 am]
BILLING CODE 4140–01–M
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
BILLING CODE 4160–01–S
VerDate Aug<31>2005
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Jkt 214001
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
E:\FR\FM\29AUN1.SGM
29AUN1
Agencies
[Federal Register Volume 73, Number 169 (Friday, August 29, 2008)]
[Notices]
[Pages 50976-50977]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-20113]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2008-N-0313]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Request for
Inspection Under the Inspection by Accredited Persons Program
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by
September 29, 2008.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974, or e-mailed to baguilar@omb.eop.gov. All comments
should be identified with the OMB control number 0910-0569. Also
include the FDA docket number found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-3793.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
[[Page 50977]]
Requests for Inspection Under the Inspection by Accredited Persons
Program--21 U.S.C. 374(g) (OMB Control Number 0910-0569)--Extension
Section 201 of the Medical Device User Fee and Modernization Act of
2002, (Public Law 107-250), amended section 704 of the Federal Food,
Drug, and Cosmetic Act by adding subsection (g) (21 U.S.C. 374 (g)).
This amendment authorized FDA to establish a voluntary third party
inspection program applicable to manufacturers of class II or class III
medical devices who meet certain eligibility criteria. On September 15,
2005, FDA issued a guidance entitled, ``Requests for Inspection by an
Accredited Person Under the Inspection by Accredited Persons Program
Authorized by Section 201 of the Medical Device User Fee and
Modernization Act 2002,'' https://www.fda.gov/cdrh/comp/guidance/
1532.html. This guidance describes the eligibility criteria and the
process for establishments to follow when requesting FDA's approval to
have an accredited person (AP), conduct a quality system regulation
inspection of their establishment under the new inspection by the
Accredited Persons Program (AP program), instead of FDA. The AP program
applies to manufacturers who currently market their medical devices in
the United States and who also market or plan to market their devices
in foreign countries. Such manufacturers may need current inspections
of their establishments to operate in global commerce.
In order to meet the eligibility criteria for requesting FDA
approval to have an AP conduct a quality system regulations inspection
of their establishment instead of FDA, applicants must submit a request
with certain information. The following information must be submitted
which shows that the applicant:
(1) ``Manufactures, prepares, propagates, compounds, or processes''
class II or class III medical devices,
(2) Markets at least one of the devices in the United States,
(3) Markets or intends to market at least one of the devices in one
or more foreign countries when one or both of the following two
conditions are met:
(a) One of the foreign countries certifies, accredits, or otherwise
recognizes the selected AP applicant as a person authorized to conduct
inspections of device establishments, or
(b) A statement that the law of a country where the applicant
markets or intends to market the device recognizes an inspection
conducted by the FDA or an AP.
(4) Provided the most recent inspection performed by FDA, or by an
AP under the AP program and inspection was classified by FDA as either
``No Action Indicated'' or ``Voluntary Action Indicated, ``and,
(5) Provided notice advising FDA of their intent to use an AP, and
identifying the AP applicant selected.
In the Federal Register of June 3, 2008 (73 FR 31692), FDA
published a 60-day notice requesting public comment on the information
collection provisions. No comments were received.
FDA estimates the burden for this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Annual Frequency per Total Annual Hours per
21 U.S.C. Section No. of Respondents Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
374(g) 100 1 100 15 1,500
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
There are approximately 8,000 foreign and 10,000 domestic
manufacturers of medical devices. Approximately 5,000 of these firms
only manufacture class I devices and are, therefore, not eligible for
the AP program. In addition, 40 percent of the domestic firms do not
export devices and therefore are not eligible to participate in the AP
program. Further, 10 to 15 percent of the firms are not eligible due to
the results of their previous inspection. FDA estimates there are 4,000
domestic manufacturers and 4,000 foreign manufacturers that are
eligible for inclusion under the AP program. Based on communications
with industry, FDA estimates that on an annual basis approximately 100
of these manufacturers may submit a request to use an AP in any given
year.
Dated: August 25, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-20113 Filed 8-28-08; 8:45 am]
BILLING CODE 4160-01-S